2023年12月29日，《中华人民共和国公司法》("《中国公司法》")修订案获采纳，于2024年7月1日生 效。新《中国公司法》引入的修订包括但不限于改革公司资本制度及组织架构、加强对少数股东权益的 保护、强化控股股东、董事及高级管理人员的责任以及准许以审计委员会取代监事会。为确保上市公司 能有效遵守及实施《中国公司法》的新规定，中国证券监督管理委员会于2025年3月28日发布了多份重 要文件，包括经修订的《上市公司章程指引》。 格隆汇1月20日丨劲方医药-B(02595.HK)公告，公司拟向公司股东提呈建议，取消公司监事会("监事会") 及修订公司现行组织章程细则。 鉴于上述情况，董事会建议对现行组织章程细则作出若干修订，主要包括但不限于(1)取消监事会，根 据《中国公司法》的规定以审计委员会行使其职能及权力；(2)加强对股东权益的保护；(3)根据适用法 律法规的变更对组织章程细则的条文作相应修订；及(4)其他内部事务及杂项变更。 ...

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性 或完整性亦不發表任何聲明，並明確表示概不就因本公告全部或任何部分內容而產生或因依賴 該等內容引致的任何損失承擔任何責任。 鑒於上述情況，董事會建議對現行組織章程細則作出若干修訂，主要包括但不限 於(1)取消監事會，根據《中國公司法》的規定以審計委員會行使其職能及權力； (2)加強對股東權益的保護；(3)根據適用法律法規的變更對組織章程細則的條文作 相應修訂；及(4)其他內部事務及雜項變更（「建議修訂」）。 1 GenFleet Therapeutics (Shanghai) Inc. 勁方醫藥科技（上海）股份有限公司 （於中華人民共和國註冊成立的股份有限公司） （股份代號：2595） 建議取消監事會及修訂組織章程細則 勁方醫藥科技（上海）股份有限公司（「本公司」）董事（「董事」）會（「董事會」）謹此 宣佈，本公司擬向本公司股東（「股東」）提呈建議，取消本公司監事會（「監事會」） 及修訂本公司現行組織章程細則（「組織章程細則」）。 建議取消監事會及修訂組織章程細則 2023年12月29日，《中華人民共和國公司法》（「《中國公司法 ...

股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 截至月份: 2025年12月31日 狀態: 新提交 致：香港交易及結算所有限公司 公司名稱: 勁方醫藥科技 ( 上海 ) 股份有限公司 （於中華人民共和國註冊成立的股份有限公司, 「本公司」） 呈交日期: 2026年1月7日 I. 法定/註冊股本變動 | 1. 股份分類 | 普通股 | 股份類別 | H | | | 於香港聯交所上市 (註1) | | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 02595 | 說明 | | | | | | | | | | | 法定/註冊股份數目 | | | 面值 | | | 法定/註冊股本 | | | 上月底結存 | | | 338,029,020 | RMB | | 0.1 | RMB | | 33,802,902 | | 增加 / 減少 (-) | | | | | | | RMB | | | | 本月底結存 | | | 338,029,020 | RMB | | 0.1 | ...

Core Viewpoint - The article discusses the imminent adjustment period for the Hong Kong Stock Connect, highlighting the potential inclusion of 31 new stocks, including Jinfang Pharmaceutical, which is expected to meet the entry criteria due to its stable market performance [1][2]. Group 1: Company Performance - Jinfang Pharmaceutical's average market capitalization during the review period is reported at HKD 10.296 billion, exceeding the threshold of HKD 9.242 billion by over HKD 1 billion, indicating a strong likelihood of inclusion in the upcoming adjustment [2]. - The stock experienced significant volatility post-IPO, with a peak increase of 115.79% from the issue price, followed by a decline of 29.31% over a month, reflecting market fluctuations and investor sentiment [3][10]. - After reaching a market cap below HKD 10 billion on October 22, the stock quickly stabilized, avoiding further price bubble risks, aided by its IPO structure which limited short-term selling pressure from retail investors [11]. Group 2: Market Context - The Hong Kong innovative drug sector has seen a substantial rally, with the Hang Seng Healthcare Index rising from a low of 2152.38 points to a high of 4726.41 points, marking a maximum increase of 119.59% over eight months [10]. - Jinfang Pharmaceutical's IPO was highly successful, with a subscription rate of 2662.79 times for the public offering, reflecting strong institutional interest in the KRAS inhibitor sector [10]. - The stock's performance is also influenced by broader market trends, as the Hang Seng Healthcare Index experienced an 11.05% correction in October, impacting investor behavior and contributing to Jinfang's price volatility [10]. Group 3: Technical Analysis - Following a significant drop on October 22, Jinfang Pharmaceutical's stock price rebounded sharply, indicating strong buying interest and a potential shift in market sentiment [4][6]. - The stock has entered a phase of stable horizontal consolidation, with a high concentration of shares held by investors, which reduces the likelihood of significant price fluctuations in the near term [6]. - The average cost of shares held by investors remains around HKD 37, which is significantly above the current market price, further discouraging selling and stabilizing the stock [6].

Major Events - Chuangsheng Group-B (06628) announced updated efficacy data for osemitamab triple therapy as a first-line treatment for gastric or gastroesophageal junction adenocarcinoma at ESMO Asia [1] - Strength Development (01277) plans to acquire 100% equity of Taiyuan Shidi for approximately 384 million yuan and acquire Dongzhimen property for a total of 86.33 million yuan [1] - Innovent Biologics (01801) completed a global strategic collaboration with Takeda Pharmaceutical and issued 6.9138 million shares under general authorization [1] - Ascentage Pharma-B (06855) received FDA and EMA approval for global registration of a Phase III clinical trial for Nilotinib as a first-line treatment for Ph+ ALL [1] - Baiao Saitou-B (02315) announced that its business partner IDEAYA received IND approval from the FDA for IDE034 [1] - Jinfang Pharmaceutical-B (02595) initiated a registration clinical trial for GFH375, the world's first oral KRAS G12D inhibitor in a controlled chemotherapy Phase III study [1] - Xixiangfeng Group (02473) signed a business cooperation agreement with Hello Car Rental to develop car rental services in designated cities under a "co-branded store" model [1] - International Commercial Settlement (00147) signed a computer chip sales agreement with Hong Kong Antarctic Light to seize growth opportunities in the IC chip market [1] - CSPC Pharmaceutical Group (01093) received clinical trial approval in the U.S. for a GLP-1/GIP receptor dual agonist injection [1] - MIRXES-B (02629) plans to collaborate with Crystal Technology to build an AI-enabled integrated "diagnosis and treatment" research and industrialization platform [1] - Zhengtong Automobile (01728) intends to invest approximately 816 million yuan to acquire Xiamen Xinda 4S dealership and automotive sales and export business [1] - Guorui Life (00108) plans to acquire 78.3% of Beijing Chunyu Tianxia Software for 269 million yuan [1] - Innovent Biologics (01801) successfully included seven innovative products (including new indications) in the 2025 National Medical Insurance Drug List [1] - Peijia Medical-B (09996) had its registration application for the TaurusNXT® "non-aldehyde cross-linked" transcatheter aortic valve replacement system accepted by the National Medical Products Administration [1] - Fosun Pharma (02196) had new drugs included in the National Medical Insurance Directory and commercial insurance innovative drug directory [1] - Junshi Biosciences (01877) had Tuoyi® new indications and Junshida® included in the National Medical Insurance Directory [1] - Valiant Biotech-B (09887) presented clinical data for LBL-034 at the 67th ASH Annual Meeting [1] - Canfite BioPharma (09926) had all approved indications for five marketed drugs successfully included in the latest National Medical Insurance Drug List [1] - Fuhong Hanlin (02696) had Fuzhuoning® (Citrus Acid Vovizili Capsules) included in the National Medical Insurance Drug List [1] - Green Leaf Pharmaceutical (02186) successfully included five new products in the 2025 National Medical Insurance Drug List or commercial insurance innovative drug directory [1] - Yinnuo Pharmaceutical-B (02591) had its core products included in the National Medical Insurance Drug List [1] Operating Performance - Poly Real Estate Group (00119) reported a contract sales amount of approximately 47.7 billion yuan for the first 11 months, a year-on-year decrease of 8.45% [2] - GAC Group (02238) reported November automobile sales of approximately 179,700 units, a year-on-year decline of 9.72% [2] - Xiehe New Energy (00182) reported an equity power generation of 697.23 GWh in November, a year-on-year increase of 7.77% [2]

Core Viewpoint - The announcement highlights the initiation of a pivotal Phase III trial (GFH375X1301) for the oral KRAS G12D inhibitor GFH375, targeting previously treated patients with KRAS G12D mutation metastatic pancreatic cancer, marking a significant advancement in the treatment landscape for this aggressive cancer type [1][2]. Group 1: Clinical Development - The Phase III trial will be conducted at approximately 40 centers, aiming to enroll around 320 patients who have previously received at least one standard systemic treatment for metastatic pancreatic cancer [2]. - GFH375 is currently in the leading tier of global oral KRAS G12D inhibitors, with multiple clinical explorations ongoing both in China and internationally [1][2]. Group 2: Market Context and Need - Pancreatic cancer is characterized by high malignancy and poor prognosis, with a 5-year survival rate of less than 10%, and the global incidence of new cases is projected to exceed 770,000 by 2037 [2]. - Approximately 40% of pancreatic cancer patients exhibit the KRAS G12D mutation, which is an independent prognostic marker associated with poor response rates and overall survival in advanced PDAC [2]. Group 3: Company Insights - The Chief Medical Officer of the company emphasized that this is the first global oral RAS inhibitor clinical study for pancreatic cancer, showcasing the company's capabilities in clinical research and integrated drug development [3]. - The company anticipates positive outcomes from the GFH375X1301 study, which could benefit patients and lead to further breakthroughs in targeted therapies for pancreatic cancer [3].

Core Viewpoint - The announcement highlights the initiation of a pivotal Phase III trial (GFH375X1301) for the oral KRAS G12D inhibitor GFH375, targeting previously treated patients with metastatic pancreatic cancer, marking a significant advancement in the treatment landscape for this aggressive disease [1][2]. Group 1: Clinical Development - GFH375 is currently in the leading tier of global oral KRAS G12D inhibitors, with multiple clinical explorations ongoing both in China and internationally [1]. - The Phase III trial will be conducted at approximately 40 centers, aiming to enroll around 320 patients who have previously received at least one standard systemic treatment for metastatic pancreatic cancer [2]. - GFH375 has received FDA Fast Track designation for the treatment of locally advanced and metastatic KRAS G12D mutant pancreatic ductal adenocarcinoma (PDAC) [1]. Group 2: Market Context - Pancreatic cancer is characterized by high malignancy and poor prognosis, with a 5-year survival rate of less than 10%, and the global incidence of new cases is projected to exceed 770,000 by 2037 [2]. - Current treatment options primarily involve chemotherapy, with objective response rates (ORR) for second-line to third-line treatments only ranging from 10% to 20%, and no standard treatment available for third-line and beyond [2]. - Nearly 40% of pancreatic cancer patients exhibit KRAS G12D mutations, which are independent prognostic markers associated with poor response rates and overall survival [2]. Group 3: Company Insights - The Chief Medical Officer of the company emphasized that this is the first global oral RAS inhibitor clinical study for pancreatic cancer, showcasing the company's capabilities in clinical research and integrated drug development [3]. - The company anticipates positive outcomes from the GFH375X1301 trial, which could benefit patients and lead to further breakthroughs in RAS-targeted therapies [3]. - GFH375 is expected to synergize with the company's dual antibody therapy for a comprehensive treatment approach to pancreatic cancer [3].

Core Viewpoint - The company has initiated a pivotal Phase III trial (GFH375X1301) for its oral KRAS G12D inhibitor GFH375, targeting previously treated patients with KRAS G12D mutant metastatic pancreatic cancer, marking a significant advancement in the treatment landscape for this aggressive cancer type [1][2]. Group 1: Clinical Development - The Phase III trial will be conducted at approximately 40 centers, aiming to enroll around 320 patients who have previously received at least one standard systemic treatment for metastatic pancreatic cancer [2]. - GFH375 is currently in the leading tier of global oral KRAS G12D inhibitors, with multiple clinical explorations ongoing both in China and internationally [1][2]. - The drug has received FDA Fast Track designation for the treatment of locally advanced and metastatic KRAS G12D mutant pancreatic ductal adenocarcinoma (PDAC) [1]. Group 2: Market Context - Pancreatic cancer is characterized by high malignancy and poor prognosis, with a 5-year survival rate of less than 10%, and the global incidence of new cases is projected to exceed 770,000 by 2037 [2]. - Approximately 40% of pancreatic cancer patients harbor the KRAS G12D mutation, which is an independent prognostic marker associated with poor response rates and overall survival in advanced PDAC [2]. Group 3: Company Insights - The Chief Medical Officer of the company highlighted that this is the first global oral RAS inhibitor clinical study for pancreatic cancer, showcasing the company's capabilities in clinical research and integrated drug development [3]. - The company anticipates positive outcomes from the GFH375X1301 study, which could benefit patients and lead to further breakthroughs in RAS-targeted therapies [3].

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性 或完整性亦不發表任何聲明，並明確表示概不就因本公告全部或任何部分內容而產生或因依賴 該等內容引致的任何損失承擔任何責任。 GenFleet Therapeutics (Shanghai) Inc. 勁方醫藥科技（上海）股份有限公司 （於中華人民共和國註冊成立的股份有限公司） （股份代號：2595） 自願公告 GFH375治療轉移性胰腺癌註冊性臨床試驗在首家研究中心啟動， 為全球首個口服KRAS G12D抑制劑單藥對照化療III期研究 本公告由勁方醫藥科技（上海）股份有限公司（「本公司」或「勁方」，連同其附屬公 司統稱「本集團」）自願刊發，以知會本公司股東及潛在投資者有關本集團最新業 務動態。 本公司董事會欣然宣佈，口服KRAS G12D (ON/OFF)抑制劑GFH375治療經治 KRAS G12D突變型轉移性胰腺癌患者的註冊性III期試驗(GFH375X1301)已在北 京大學腫瘤醫院啟動。目前GFH375開發進度位於全球口服KRAS G12D抑制劑第 一梯隊，多項GFH375（於中國境外稱VS-7375）單藥和聯合療法正在 ...

股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 截至月份: 2025年11月30日 狀態: 新提交 致：香港交易及結算所有限公司 公司名稱: 勁方醫藥科技 ( 上海 ) 股份有限公司 （於中華人民共和國註冊成立的股份有限公司, 「本公司」） | 1. 股份分類 | 普通股 | 股份類別 | H | | 於香港聯交所上市 (註1) | | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 02595 | 說明 | | | | | | | | | | 法定/註冊股份數目 | | | 面值 | | 法定/註冊股本 | | | 上月底結存 | | | 338,029,020 | RMB | | 0.1 RMB | | 33,802,902 | | 增加 / 減少 (-) | | | | | | RMB | | | | 本月底結存 | | | 338,029,020 | RMB | | 0.1 RMB | | 33,802,902 | | 2. 股份分類 | 普通股 | 股份類別 | ...